Xvivo Perfusion ABXVIPF -1.32%91 Return-on-Tangible-Equity is 21.80% as of Mar. 2026, which is 514% above its 10-year median of 3.55. GuruFocus rates XVIPF with a GF Score™ of 91/100 and a GF Value™ of $42.07 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 760 Medical Devices & Instruments companies, Xvivo Perfusion AB ranks better than 68.68% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Xvivo Perfusion AB's annualized net income for the quarter that ended in Mar. 2026 was $15.58 Mil. Xvivo Perfusion AB's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $71.49 Mil. Therefore, Xvivo Perfusion AB's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 21.80%.
The historical rank and industry rank for Xvivo Perfusion AB's Return-on-Tangible-Equity or its related term are showing as below:
XVIPF'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -14.04 Med: 3.55 Max: 23.36
Current: 10.9
During the past 13 years, Xvivo Perfusion AB's highest Return-on-Tangible-Equity was 23.36%. The lowest was -14.04%. And the median was 3.55%.
XVIPF's Return-on-Tangible-Equity is ranked better than 68.68% of 760
companies
in the Medical Devices & Instruments industry
Industry Median: 4.115
vs XVIPF: 10.90
Xvivo Perfusion AB (OTCPK:XVIPF) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Xvivo Perfusion AB Return-on-Tangible-Equity Related Terms
Xvivo Perfusion AB Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Xvivo Perfusion AB's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xvivo Perfusion AB Return-on-Tangible-Equity Chart
XVIPF vs ABT, SYK, MDT: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, Xvivo Perfusion AB's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xvivo Perfusion AB Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Xvivo Perfusion AB's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 21.80% mean?
Xvivo Perfusion AB (XVIPF) has a Return-on-Tangible-Equity of 21.80% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Xvivo Perfusion AB and its competitors. This is 514% above median its historical median of 3.55. According to the industry distribution chart, Xvivo Perfusion AB ranks #238 out of 760 companies in the Medical Devices & Instruments industry, placing it in the top 31.3%.
Is Xvivo Perfusion AB's Return-on-Tangible-Equity too high?
Xvivo Perfusion AB's current Return-on-Tangible-Equity of 21.80% is 514% above median its 10-year median of 3.55. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.12. Xvivo Perfusion AB's value of 21.80% is 429.8% above this industry median. Based on the distribution chart, Xvivo Perfusion AB ranks #238 out of 760 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Xvivo Perfusion AB has a GF Score™ of 91/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's Return-on-Tangible-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Xvivo Perfusion AB ranks #238 out of 760 companies for Return-on-Tangible-Equity. This puts Xvivo Perfusion AB in the upper half of its industry. The industry median Return-on-Tangible-Equity is 4.12. Xvivo Perfusion AB's value of 21.80% is 429.8% above this benchmark. While the company's 10-year median is 3.55 vs. the industry median of 4.12, Xvivo Perfusion AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.12, based on 760 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xvivo Perfusion AB's current Return-on-Tangible-Equity of 21.80% is 429.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Xvivo Perfusion AB and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xvivo Perfusion AB's current Return-on-Tangible-Equity is 21.80%, which is 514% above median its own 10-year median of 3.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $42.07, compared to a current price of $29.00 — trading 31.1% below its estimated fair value. The current Return-on-Tangible-Equity is 21.80%, which is 514% above median its 10-year median of 3.55 and 429.8% above the Medical Devices & Instruments industry median of 4.12. Xvivo Perfusion AB's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current Return-on-Tangible-Equity is 21.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?
Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued.
The current stock price of $29.00 is trading 31.1% below its estimated GF Value™ of $42.07.
GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.
Key valuation signals for XVIPF:
Return-on-Tangible-Equity: 21.80% (514% above median its 10-year median of 3.55)
GF Value™: $42.07 vs. price of $29.00 (31.1% below fair value)
Industry Position: 429.8% above the Medical Devices & Instruments median (#238 of 760)
No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
91GF Score
Get the complete analysis for XVIPF
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XVIPF has been successfully added to your 
